Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) CFO Sells $115,977.96 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 4,761 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total value of $115,977.96. Following the completion of the sale, the chief financial officer directly owned 40,166 shares of the company’s stock, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):

• On Thursday, July 30th, Houte Hans Van sold 2,845 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total value of $66,516.10.

Nurix Therapeutics Price Performance

NRIX opened at $25.53 on Friday. The stock’s 50 day simple moving average is $21.26 and its 200 day simple moving average is $18.06. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -7.40 and a beta of 1.79. Nurix Therapeutics, Inc. has a 1 year low of $8.19 and a 1 year high of $25.89.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The company had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. As a group, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 EPS for the current year.

Hedge Funds Weigh In On Nurix Therapeutics

A number of institutional investors have recently bought and sold shares of NRIX. BlackRock Inc. purchased a new stake in Nurix Therapeutics in the second quarter worth about $212,769,000. Deutsche Bank AG bought a new position in shares of Nurix Therapeutics in the 2nd quarter worth approximately $3,674,000. Persistent Asset Partners Ltd bought a new position in shares of Nurix Therapeutics in the 2nd quarter worth approximately $751,000. Global Retirement Partners LLC purchased a new position in shares of Nurix Therapeutics in the 2nd quarter valued at approximately $82,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Nurix Therapeutics during the second quarter valued at approximately $6,614,000.

Analyst Ratings Changes

NRIX has been the topic of a number of recent analyst reports. UBS Group raised their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Needham & Company LLC reiterated a “buy” rating and set a $34.00 target price on shares of Nurix Therapeutics in a report on Tuesday. Wall Street Zen raised Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Robert W. Baird boosted their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.